“This patent adds important value to a European commercial opportunity for vosaroxin, as it covers a wide range of its contemplated commercial use with cytarabine out to 2027,” said Eric Bjerkholt, Executive Vice President, Corporate Development and Finance of Sunesis. “Granting of this European patent is particularly timely, as we prepare to file a European Marketing Authorization Application for vosaroxin in combination with cytarabine in AML by year end. It also provides us with greater certainty in pursuing the full clinical and commercial potential of vosaroxin using various therapeutic combinations in AML and other hematologic malignancies.” (Original Source)
Shares of Sunesis Pharmaceuticals closed last Friday at $0.95, up $0.02 or 1.72%. SNSS has a 1-year high of $3.72 and a 1-year low of $0.74. The stock’s 50-day moving average is $0.88 and its 200-day moving average is $1.68.
Sunesis Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers.